Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03674892 · ClinicalTrials.gov registry record · NA
Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain
A NA study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03674892 is a NA study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 21 participants.
The verdict
NCT03674892, a NA study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is a prospective, interventional, open-label, single arm, non-randomized trial treating 30 patients with peripheral or mixed neuropathic corneal pain at their baseline exam and following 45 days and 90 days of daily use with the TrueTear™ ITN device.
Interventions
- DEVICE TrueTear™ intranasal neurostimulator (ITN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-09-28 |
| Est. Completion | 2023-09-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03674892
The ClinicalTrials.gov registry entry for NCT03674892 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TrueTear™ intranasal neurostimulator (ITN) is the first listed.
NCT03674892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03674892 about?
NCT03674892 is a clinical study titled "Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain". This study is a prospective, interventional, open-label, single arm, non-randomized trial treating 30 patients with peripheral or mixed neuropathic corneal pain at their baseline exam and following 45 days and 90 days of daily use with the TrueTear™ ITN device.
What is the current status of trial NCT03674892?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2018-09-28. Estimated completion is 2023-09-09.
What interventions are being tested in trial NCT03674892?
The interventions under investigation include: TrueTear™ intranasal neurostimulator (ITN) (DEVICE).
Who is sponsoring clinical trial NCT03674892?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.